Well, Now: What It’s Really Like to Take Ozempic

Slate News

Slate Podcasts

News, News Commentary, Politics

4.5 • 6K Ratings

🗓️ 6 October 2024

⏱️ 54 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

GLP-1 drugs like Ozempic, WeGovy, Mounjaro and others revolutionized weight loss and chronic weight management. But what does it feel like for the patients who take them? On this week’s episode of Well, Now Kavita and Maya talk with journalist and author Johann Hari. Over the course of a year, Johann dived into the research and history behind GLP-1 drugs and how they became the latest and most effective way to lose weight. All the while, he was also taking Ozempic himself. His latest book Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight-Loss Drugs takes a personal and research-based look at the revolutionary, controversial rise of GLP-1 drugs for weight management. If you liked this episode, check out: The Full Truth About Ozempic and Doctors Agree: Obesity is a Disease. The Public Needs to Catch Up. Well, Now is hosted by registered dietitian nutritionist Maya Feller and Dr. Kavita Patel. Podcast production by Vic Whitley-Berry with editorial oversight by Alicia Montgomery. Send your comments and recommendations on what to cover to wellnow@slate.com Want to listen to Well, Now uninterrupted? Subscribe to Slate Plus to immediately unlock ad-free listening to Well, Now and all your other favorite Slate podcasts. Subscribe now on Apple Podcasts by clicking “Try Free” at the top of our show page. Or, visit slate.com/wellplus to get access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

Transcript

Click on a timestamp to play from that location

0:00.0	This episode is brought to you by the award-winning Thought Park.
0:05.0	Swop the True Crime Pods for something really screenworthy with Fright Knights at Thought Park.
0:11.0	Europe's top theme park scare event is back.
0:14.0	Take on spine-tingling scaremases, explore blood-chilling scare zones and shows,
0:19.5	and summon the nerve to ride roller coasters in the dark, including Hyperia, the UK. and the Sunshine, I'm running in the rain. I hate this weather.
0:37.0	Not me.
0:41.0	Ugh, Still 6K. I know I'm exhausted. You're right. I love running too. If you don't hate running a little, you don't love running enough.
0:55.0	Run with Nike.
0:57.0	Visit Nike.com slash running to learn more. You're listening to Well Now,
1:06.1	You're listening to Well Now,
1:07.5	Slate's podcast on Health and Wellness.
1:09.6	I'm Maya Fellow.
1:10.6	And I'm Kavita Patel.
1:12.4	It has been years since the FDA approved Ozembic and other similar drugs in the
1:18.1	G. L. P. 1 class for chronic weight management and chronic disease. Maya, I feel like we're still talking about it non-stop.
1:26.0	Kavita, I couldn't agree more.
1:28.0	It is the conversation of the moment and continues to be.
1:31.0	GLP1 drugs like Ozempik and W Wagoi, which are the same thing, have completely changed the conversation
1:36.6	about weight loss.
1:38.0	While these drugs haven't been used to treat obesity for long compared to other drugs, the results we're seeing so far
1:44.3	cannot be ignored for example in clinical trials people taking Ozempik lost nearly
1:50.7	15% of their body weight after a little over a year taking the drug.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Slate Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Slate Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.